Sitagliptin
DPP-4 Inhibitor- Drug Class
- DPP-4 Inhibitor
- Mechanism of Action (MOA)
- Inhibits DPP-4 → ↑ endogenous incretins (GLP-1, GIP) → glucose-dependent insulin release.
- Clinical Notes
- Weight-neutral with low hypoglycemia risk. Rare pancreatitis and arthralgia.
- Source
- FDA label (DailyMed)
Sources
Reviewed June 2026- FDA label (DailyMed) — FDA / DailyMed
Checked against the guideline or standard reference the exam keys to. If it has moved, use Report an error below.
Same family
Got a pharmacology lecture that covers Sitagliptin? Turn it into flashcards and board-style questions, free. Drop it on the home page
All pharmacology